



« **Oncology: key issues for the future** »

Success of the first BioAlliance Pharma's symposium

Paris, March 20th, 2012 – BioAlliance Pharma SA (Euronext Paris - BIO), a Company dedicated to specialty and orphan pharma products in oncology and supportive care, has successfully held its first symposium today at its headquarter in Paris, with about 50 shareholders, fund managers, analysts and media representatives.

The presentations of this half-day symposium were focused on several key issues of oncology:

- Bertrand Vergely, a Philosopher and Theologian, has proposed a philosophical point of view on care and taking care about one's fellow human beings as fundamentals of our societies.
- Dr Jean-Pierre Armand, an internationally known Oncologist, has presented the major aspects of cancerology, the available treatments and the future research topics.
- Pr. Philippe Merle, Professor in Hepatology (La Croix Rousse Hospital, Lyon, France) and principal investigator of the Livatag[®] phase III clinical trial to come, has explained the epidemiology of the primary liver cancer and the different treatments available today. He has also presented the development program of Livatag[®] (doxorubicine transdrug[™]) in this indication.
- Pr. Michael Henke, Professor in Radiotherapy (Universitätsklinikum Freiburg, Germany), has shared with the audience his experience and expertise in oral mucositis, a particularly invalidating alteration of the oral mucosa, induced by radio and –chemotherapy cancer treatments.

« *We were delighted to gather leader experts in oncology to share their experience as clinicians and researchers with our main shareholders, fund managers, analysts and media representatives in a didactic half-day symposium* », stated Judith Greciet, General Manager of BioAlliance Pharma.

“This half-day was focused on our orphan product portfolio in oncology of which its advanced key assets, notably Livatag[®] and clonidine Lauriad[™], represent strong growth leverages for the Company.

It was also an opportunity to share our enthusiasm for these projects which meet important medical needs. I hope this meeting has enabled everyone to better understand the key issues of cancer research and hence of the treatments we are developing”, added Judith Greciet.

**The videos and summaries of this symposium will be available on
BioAlliance Pharma’s website on Thursday 29 March, 2012 (www.bioalliancepharma.com)**

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc[®]/Oravig[®] (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir[®] (Acyclovir Lauriad[™]) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad[™] (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products

Livatag[®] (Doxorubicin Transdrug[™]) in primary liver cancer: Authorization for Phase III clinical trial

Clonidine Lauriad[™] (mucositis): Phase II on going

AMEP[™] (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA’s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Judith Greciet, CEO
Tel +33 1 45 58 76 00

judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com